Recent Finacing
Recent Raise
adivo develops species-specific therapeutic antibodies for canine cancer and chronic inflammatory diseases using a fully synthetic phage-display library that mimics the canine immunoglobulin repertoire, licensed from MorphoSys.
Focus Areas
Recent Investors
Funding round
Investors